What is Tesamorelin?
i. Tesamorelin is a growth hormone releasing hormone (GHRH) analog that has been shown to increase IGF-1 levels in men by an average of 181 micrograms/liter. It binds and stimulates human GHRH receptors with similar potency as endogenous GHRH. Other benefits include nootropic effects (better cognition), reducing triglycerides, decreased thickness of carotid artery walls, decreased visceral fat tissue, and decreased C-reactive protein, a marker of inflammation.
How does it work?
Tesamorelin stimulates the pituitary gland in the brain to secrete growth hormone. Clinical trials have shown that Tesamorelin significantly reduces abdominal fat with fewer side effects than HGH itself. Tesamorelin has also been shown to reduce lipodystrophy in HIV-infected individuals. Tesamorelin increases growth hormone release and was shown to improved several measures of cognitive function in cognitively normal and mildly impaired older individuals in a placebo-controlled trial. In a study, scores on standard tests of executive functions and verbal memory were significantly higher in participants given Tesamorelin in a 20-week trial, according to Laura D. Baker, PhD. Participants taking the drug in the 78-person trial also reported greater subjective improvement in cognition relative to the placebo group.
A 2006 clinical trial with GHRH found small but significant improvements in cognitive test scores in healthy older adults. In the current study, funded by the National Institute on Aging, 41 cognitively normal adults and 37 with mild cognitive impairments were randomized to get a placebo or Tesamorelin at 1mg per day subcutaneously. Average participant age was 66 to 70 among four groups. Scores on the Mini-Mental State Examination averaged 29 for the normal participants and 28 for those with mild impairments. Normal and impaired participants differed more at baseline on a test of story recall, with average scores of 54-44 respectively. Tesamorelin appeared to have a protective effect relative to the placebo among cognitively impaired patients on this measure. At final evaluation, scores declined AN average of five points with the placebo, WHEREAS those assigned to Tesamorelin HAD an average decline of less than one point.
Side effects are mild and rare. You may experience the following when taking Tesamorelin:
- Mild rash or itching
- Muscle spasms
- Redness, swelling, or irritation at injection site